Compare ACCO & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCO | BWAY |
|---|---|---|
| Founded | 1893 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Publishing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.9M | 337.9M |
| IPO Year | N/A | 2019 |
| Metric | ACCO | BWAY |
|---|---|---|
| Price | $3.81 | $16.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 839.1K | 61.9K |
| Earning Date | 10-30-2025 | 11-11-2025 |
| Dividend Yield | ★ 7.94% | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | ★ 0.43 | 0.13 |
| Revenue | ★ $1,544,000,000.00 | $49,094,000.00 |
| Revenue This Year | N/A | $330.76 |
| Revenue Next Year | $0.83 | $22.24 |
| P/E Ratio | ★ $8.75 | $51.24 |
| Revenue Growth | N/A | ★ 27.08 |
| 52 Week Low | $3.20 | $7.84 |
| 52 Week High | $5.83 | $18.18 |
| Indicator | ACCO | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 61.82 | 46.21 |
| Support Level | $3.74 | $16.75 |
| Resistance Level | $3.86 | $17.38 |
| Average True Range (ATR) | 0.09 | 0.75 |
| MACD | 0.04 | -0.07 |
| Stochastic Oscillator | 86.17 | 21.06 |
ACCO Brands Corp designs, manufactures, and markets consumer and business products. It operates through two segments: ACCO Brands Americas, and ACCO Brands International. The company offers school notebooks, janitorial supplies, and whiteboards; storage and organization products, sheet protectors, and indexes, and punching products; computer accessories and others used in schools, homes, and businesses. The company markets and sells its products through various channels, including mass retailers; e-tailers; discount, and variety chains; and warehouse clubs. It generates maximum profit from ACCO Brands America segment.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.